Skip to main content
FDA headquarters.

Strides Pharma obtains FDA clearance for generic Actigal


Patients with Primary Biliary Cirrhosis will soon have a new generic treatment available.

Strides Pharma’s subsidiary, Strides Pharma Global, Singapore, has received The Food and Drug Administration’s nod for Ursodiol capsules in a dosage strength of 300 mg.

The medication is the generic of Allergan’s Actigal capsules.

Ursodiol capsules had a market value of approximately $45 million, according to IQVIA November data.

The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma in the United States. 

This ad will auto-close in 10 seconds